Client-directed therapy technique drastically reduces divorce/separation ratesNovember 16, 2009Using four simple questions to generate client-directed feedback can greatly increase the chances that struggling couples will stay together, according to a recently published study. According to the largest clinical trial with couples to date - which was co-authored by University of Rhode Island Human Development and Family Studies Professor Jacqueline Sparks - couples that had systematic client feedback incorporated into their sessions were 46.2 percent less likely to wind up divorced or separated. The largest clinical trial to date, the findings of the study were published in the Aug. 3 issue of the Journal of Consulting and Clinical Psychology. Sparks co-authored the two-year study - conducted at the Vestfold Family Counseling Center in Norway - with Barry Duncan of Heart and Soul of Change Project and Morten Anker of the Family Counseling Office in Vestfold. The team of U.S. and Norwegian researchers studied 205 randomly selected couples from southern Norway for two years from October 2005 through December 2007. The couples showed problems typical of struggling relationships, from communication problems to infidelity and physical or psychological issues. Half of the couples in the study used the client feedback system, while the other half did not. The couples using the feedback methods used a visual scale at the start of each session to rate their well being in four categories - individual, interpersonal, social and overall. Using the Outcome Rating Scale system as a guide, approaches for therapy could be altered in real time, helping to open lines of communication between clients and therapists. This, in turn, helped give the client a sense of ownership in their healing process. "According to the research, when clients believe they - not the therapist - are responsible for change, results are better and last longer," Sparks said. "In some therapy, clients can become passive and wait for the therapist to come up with the 'magic bullet.' If they get better, they figure it was the therapist. These kinds of situations often lead to dependency, where clients are reluctant to end treatment or get caught in a kind of treatment revolving door-after therapy they lose ground and return." Participants in the study were contacted six months after their final therapy session. Couples using the Outcome Rating Scale reported feeling more satisfied in their relationships, with only 18.4 percent of those couples indicating they had separated or divorced, compared to 34.2 percent for those couples who didn't have client-based feedback incorporated into their sessions. "The most important element for successful therapy is client engagement," Sparks said. "When clients buy into the process, believe it will be helpful, and participate with the therapist in working on difficulties, they will have better outcomes." While the Outcome Rating Scale system helped couples, it also improved the performance rates of therapists. Therapists participating in the study were trained on how to integrate the findings of the Outcome Rating Scale into their counseling sessions. "We know that therapists vary significantly in how skilled they are in engaging clients," Sparks said. "In our study, when poorer performing therapists asked for and used client feedback, they improved enough to rank with the best performing therapists. So, therapist variability was reduced, with feedback being the leveler. When this happened, given that our sample was large enough to actually tell us something, we found the superior effect for feedback couples." University of Rhode Island |
|||||||||||||||||||||
| Related Clinical Trial Current Events and Clinical Trial News Articles Drug shows promise for Huntington's disease An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology. Lower detection of prostate cancer with PSA screening in US than in a European randomized trial Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute. New vaccine effective in preventing TB in African patients with HIV infection Investigators from Dartmouth Medical School (DMS) have reported results of a clinical trial showing that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection. Discovery of mechanism in brain cell injury in Huntington's offers new treatment approaches Scientists at the Brain Research Centre and Centre for Molecular Medicine and Therapeutics have uncovered a key cellular mechanism that alters brain cell function in Huntington's disease, and identified a possible treatment for the disease. Vaccine approach extends life of metastatic prostate cancer patients In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations. Medical students may soon be tested on evolution What does evolution - a field that often deals with changes over many generations - have to do with preventing and treating disease in our lifetime? Genes found linked to breast cancer drug resistance could guide future treatment choices Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs. Herpes medication does not reduce risk of HIV transmission, UW-led international study finds A five-year international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment taken twice daily to suppress herpes simplex virus-2 (HSV-2), which is the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2. Researchers find a treatment for deadly brain tumor New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy. First successful use of expanded umbilical-cord blood units to treat leukemia Scientists at Fred Hutchinson Cancer Research Center have cleared a major technical hurdle to making umbilical-cord-blood transplants a more widely-used method for treating leukemia and other blood cancers. More Clinical Trial Current Events and Clinical Trial News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||